Recursion (RXRX) Gets FDA Alignment on REC-4881 Phase 3 Design

Recursion (RXRX) announced alignment with the FDA on the Phase 3 design for REC-4881, with trial initiation planned for the second half of 2027. The study aims to enroll around 200 patients, following Phase 2 results.

Original reporting
Published Nov 18, 2026, 9:59 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 10:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Recursion (RXRX) Gets FDA Alignment on REC-4881 Phase 3 Design — source image
Decision brief

The 30-second read

$RXRXBullishMed
01

Why it matters

FDA alignment signals regulatory confidence, but the trial start is over a year away, so price reaction may be modest.

02

Market read

The announcement provides a new data point for investors tracking biotech pipeline milestones.

03

What to watch

Potential competition in the same indication and the need for additional funding before trial start.

Relevance 8/10Novelty 8/10Timing: post‑announcement today

Background

Recursion is a clinical‑stage biotech focused on AI‑driven drug discovery. The REC‑4881 program targets a specific oncology indication.

Company-level read

Ticker impact

$RXRXBullishMedium confidence
Context

Recursion announced FDA alignment on the Phase 3 design for its REC-4881 oncology trial, a new development milestone.

Expected impact

potential upside as investors price in reduced risk and future data milestones

Evidence & confidence

While the news is material, the trial will not start until H2 2027, limiting immediate price impact.

Market effects

Adds confidence to the broader biotech sector's pipeline progression outlook.

Minimal regional effect; primarily U.S. biotech investors.

Limited global relevance beyond biotech investors.

Counterpoint

The long timeline to data may dilute the news impact; investors could remain cautious.

Key entities

  • Recursion Pharmaceuticals

    US‑listed biotech (RXRX) developing REC‑4881.

Related articles

$RXRXMed

Recursion Aligns With FDA On Phase 3 Trial Design For FAP Drug REC-4881; Stock Up

Recursion Pharmaceuticals (RXRX) aligned with the FDA on the Phase 3 trial design for REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP). The trial, expected to start in late 2027, will assess composite event-free survival as the primary endpoint. REC-4881 has shown a 47% median reduction in total polyp burden in Phase 1b/2 trials. RXRX shares were up 4.41% in premarket trading.

$RXRXMedAI 8/10

Recursion (RXRX) Q3 2026 Earnings Call Transcript

Recursion (RXRX) reported Q3 2026 earnings, highlighting clinical data for REC-4881 and REC-1245. REC-4881 showed significant reductions in polyp burden and safety. REC-1245 demonstrated early activity in solid tumors. The company secured $535M in partner cash inflows and extended cash runway to 2029. Operating expenses for 2026 were lowered to $375M, with 2027 expected under $360M. Sanofi and Roche collaborations advanced, with milestones and royalties. Fred Hassan was appointed board chair.

$RXRXMedAI 8/10

What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call

Recursion Pharmaceuticals (RXRX) reported Q3 updates, including 55% and 50% median reductions in upper and lower GI polyp burdens, respectively. REC-1245 showed partial responses in advanced solid tumors. Sanofi exercised an option, triggering a $10M payment. RXRX raised $200M in financing, extending cash runway into 2029. The company expects to start a registrational study in 2H 2027.

$RXRXHighAI 8/10

Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues

Recursion Pharmaceuticals reported a narrower-than-expected Q3 2026 loss of 22 cents per share, with revenues of $18.55 million, up 258.5% YoY, driven by a $10 million Sanofi milestone payment. Operating expenses declined, and the company advanced its pipeline, including REC-4881 and REC-1245. RXRX shares are down 6.4% YTD.

$RXRXMedAI 8/10

Recursion Pharma Q3 Net Loss Narrows, Reports Positive REC-4881 Data; Advances Pipeline

Recursion Pharmaceuticals (RXRX) reported Q3 2026 net loss narrowed to $119.0M from $162.3M YoY. Revenue rose to $18.55M, driven by a $10M Sanofi milestone payment. REC-4881 showed positive FAP trial results, with significant polyp burden reductions. REC-1245 demonstrated preliminary efficacy in cancers. RXRX expects cash to last into 2029. Stock is down 4.96% to $3.83.